1 Department of Internal Medicine, and the 3 Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Conneticut 06520-8020 and 2 Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106-4951
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Net hepatic glycogenolysis and gluconeogenesis
were examined in normal (n = 4) and
cirrhotic (n = 8) subjects using two
independent methods [13C
nuclear magnetic resonance spectroscopy (NMR) and a
2H2O
method]. Rates of net hepatic glycogenolysis were calculated by
the change in hepatic glycogen content before (~11:00 PM) and after
(~7:00 AM) an overnight fast using
13C NMR and magnetic resonance
imaging. Gluconeogenesis was calculated as the difference between the
rates of glucose production determined with an infusion of
[6,6-2H2]glucose
and net hepatic glycogenolysis. In addition, the contribution of
gluconeogenesis to glucose production was determined by the 2H enrichment in C-5/C-2 of blood
glucose after intake of
2H2O
(5 ml/kg body water). Plasma levels of total and free insulin-like growth factor I (IGF-I) and IGF-I binding proteins-1 and -3 were significantly decreased in the cirrhotic subjects
(P < 0.01 vs. controls).
Postprandial hepatic glycogen concentrations were 34% lower in the
cirrhotic subjects (P = 0.007). Rates
of glucose production were similar between the cirrhotic and healthy
subjects [9.0 ± 0.9 and 10.0 ± 0.8 µmol · kg body
wt1 · min
1,
respectively]. Net hepatic glycogenolysis was 3.5-fold lower in
the cirrhotic subjects (P = 0.01) and
accounted for only 13 ± 6% of glucose production compared with 40 ± 10% (P = 0.03) in the control
subjects. Gluconeogenesis was markedly increased in the cirrhotic
subjects and accounted for 87 ± 6% of glucose production vs.
controls: 60 ± 10% (P = 0.03).
Gluconeogenesis in the cirrhotic subjects, as determined from the
2H enrichment in glucose C-5/C-2,
was also increased and accounted for 68 ± 3% of glucose production
compared with 54 ± 2% (P = 0.02) in the control subjects. In conclusion, cirrhotic subjects have increased rates of gluconeogenesis and decreased rates of net hepatic
glycogenolysis compared with control subjects. These alterations are
likely important contributing factors to their altered carbohydrate metabolism.
13C nuclear magnetic resonance spectroscopy; 2H2O; insulin-like growth factor I
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
ALTHOUGH HEPATIC GLUCOSE metabolism is generally agreed to be altered in patients with chronic liver failure, the specific alterations remain unclear. Rates of glucose production have been reported to be both normal (5, 32, 33, 45) and decreased (13, 26, 29, 36) in patients with liver cirrhosis. Glycogen metabolism has also been suggested to be altered in patients with liver cirrhosis, but, due to the invasiveness of the liver biopsy technique, this conclusion is based on limited biopsy data. Splanchnic balance studies have found that amino acid and lactate uptake is increased in cirrhotic subjects, accounting for ~90% of splanchnic glucose production, which suggests gluconeogenesis is increased in patients with liver cirrhosis, but this approach is indirect and relies on assumptions in regard to the intrahepatic fate of the C-3 precursors. In contrast, recent studies using [14C]glycerol found no differences in 14C incorporation into glucose, suggesting that gluconeogenesis is not altered in patients with liver cirrhosis. However, this method is also indirect and only quantifies gluconeogenesis from glycerol, which under most circumstances is a minor gluconeogenic precursor (18).
To address these questions, we applied two independent methods to assess gluconeogenesis in normal and cirrhotic subjects after an overnight fast. 13C nuclear magnetic resonance (NMR) spectroscopy was used to measure directly hepatic glycogen content and hence rates of net hepatic glycogenolysis (40). Rates of gluconeogenesis were estimated by subtracting the rates of net hepatic glycogenolysis from the rates of glucose production determined using [6,6-2H2]glucose. From the ratios of the 2H enrichments of the hydrogen bound to C-5 and C-2 of blood glucose after oral intake of 2H2O (21), the fractional contributions of gluconeogenesis to rates of glucose production were determined. Rates of gluconeogenesis were calculated by multiplying those ratios by the rates of glucose production.
![]() |
METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Subjects. Eight subjects with biopsy-confirmed cirrhosis of the liver (5 men and 3 women, age: 43 ± 1 yr, wt: 86 ± 6 kg, body mass index: 27 ± 1 kg/m2) were studied. All patients had hepatitis C [except 1 patient who had cryptogenic (micronodular) cirrhosis]. All were in stable condition, without signs of encephalopathy or peripheral edema; two had minimal ascites as confirmed by the abdominal magnetic resonance imagine (MRI) examination. Two patients had experienced esophageal variceal bleeding episodes more than three years before the study. The control group consisted of four lean, healthy volunteers matched for age and body weight (3 men and 1 woman, age: 38 ± 4 yr, wt: 82 ± 6 kg, body mass index: 25 ± 1 kg/m2). All study participants were instructed to eat a diet containing ~150 g carbohydrate/day and to abstain from alcohol, caffeine, and exercise except for normal daily activities for 3 days before the study. The protocol was approved by the Yale University Human Investigation Committee, and informed consent was obtained from each subject.
Study protocol. On the day of the
study, the subjects were admitted to the Yale University/New Haven
Hospital General Clinical Research Center (GCRC) between 3:00 and 4:00
PM. At 5:00 PM [time (t) = 0 h], dinner in the form of a liquid meal (~450 ml) consisting of
1,000 kcal [60% carbohydrate (80% of which was in the form of
free glucose), 20% protein, and 20% fat] was ingested over a
10-min period. At 9:00 PM, the subjects were brought to the Magnetic
Resonance Center (MRC) and were placed in a 2.1 T NMR spectrometer
(Bruker Biospec Spectrometer, Billerica, MA), and liver glycogen
concentration was measured continuously with
13C NMR spectroscopy from 10:00 to
11:00 PM (t = 5-6 h). Hereafter, the subjects were brought back to the GCRC and given a total of 5 ml/kg
body water of
2H2O
(99.9% 2H; Isotec, Miamisburg,
OH) to drink. The volume was divided into three portions of equal size
and was given at 11:45 PM (t = 6 h and
45 min), 12:45 AM (t = 7 h and 45 min), and 1:30 AM (t = 8 h and 30 min)
to minimize discomfort such as light dizziness or nausea, which has
been reported (20). Water ingested ad libitum during the fast was
enriched 0.5% with
2H2O
to maintain isotopic steady state. From 6:00 AM to 7:00 AM (t = 13-14 h) the
13C NMR measurements of hepatic
glycogen concentration were repeated, whereafter the subjects were
brought back to the GCRC. To avoid physical activity during the study,
the subjects were transported in a wheelchair between the MRC and the
GCRC. In the GCRC, all subjects remained in bed at all times. A
catheter was placed retrogradely in a hand vein for blood collection.
This hand was kept in a hot box at 70°C to arterialize the blood
samples, and basal blood samples were collected. After placement of an
antecubital intravenous catheter in the contralateral arm for infusion,
a primed (275 µmol/m2)
continuous [4.89
µmol/(m2 · min)1]
infusion of
[6,6-2H2]glucose
(Cambridge Isotopes Laboratories, Andover, MA) was begun and continued
for 240 min (7:30 to 11:30 AM) for determination of rates of glucose
production. After 200 min of infusion, blood samples were taken every
10 min for the next 40 min of infusion for determination of
[6,6-2H2]glucose
(m + 2) enrichment. Blood
was collected at 0 min (14.5-h fast), 60 min (15.5-h fast), 180 min
(17.5-h fast), and 240 min (18.5-h fast) for determination of
2H enrichment of the hydrogens
bound to C-2 and C-5 of blood glucose and at 240 min for determination
of 2H enrichment in body water.
After the last blood sample, the intravenous lines were removed, and
the subjects were given a regular meal.
The volume of the liver was measured upon admission after ingestion of the meal by clinical imaging on a 1.5-T magnet (Signa II; General Electric, Milwaukee, WI) using multiecho axial scanning (TE20/80, TR2000). In two healthy subjects, MRI of liver volume was performed 2 days after the study. The data were transferred to an independent work station (ISG, Toronto, Canada) and processed with the CAMRA S200 Program (ISG) that provided three-dimensional image reconstruction and volume determinations. Accuracy of the measurement was assessed with water-filled phantoms of known volume and was determined to be ±5% with a coefficient of variation of ±1%.
To assess glucose tolerance to the mixed meal, the cirrhotic subjects were admitted to the GCRC on a separate day after an overnight fast. A liquid mixed meal identical to the one given during the initial study {~450 ml, 1,000 kcal [60% carbohydrate (80% in the form of free glucose), 20% protein, and 20% fat]} was given, and blood was collected every 30 min (t = 0-300 min) for determination of plasma glucose concentrations.
13C NMR spectroscopy. The subjects were placed in the supine position in a 2.1-T Bruker Biospec Spectrometer, and, from 10:00 PM to 11:00 PM (5-6 h into the fast) and from 6:00 AM to 7:00 AM (13-14 h into the fast), 13C NMR spectra were obtained with a 9-cm circular 13C observation coil, and a 12 × 14-cm coplanar butterfly 1H decoupler coil was placed rigidly over the lateral aspect of the abdomen as previously described (9). In brief, initial coil placement was determined by percussion of the borders of the liver, and the position of the coil over the liver was confirmed by imaging the liver from the surface coil with a multislice gradient echo image. The magnet was shimmed with the water signal obtained from the decoupling coil. Localized 13C NMR liver spectra were obtained with a modified one-dimensional inversion-based sequence for surface suppression. On the basis of 1H density profiles of the sequence, <15% of the glycogen signal could arise from tissues within 2.5 cm of the surface of the subject, assuming equal glycogen concentration throughout the volume of observation. In each subject, all skin and muscle was within 2.5 cm of the surface as assessed by the image. Heating from decoupling radio frequency calculated with a magnetic vector potential model was <4 watts/kg of tissue, which is below Food and Drug Administration limits for local heating. Spectra were processed with a mild 30-Hz Lorentzian to Gaussian filter and a 500-Hz convolution difference. After processing, the glycogen line width was 70-90 Hz. Resonance intensity was measured by integrating over a bandwidth of ±120 Hz. The glycogen concentration of liver was determined by comparing the signal intensity obtained with the localized spectroscopy sequence in vivo with the signal intensity obtained from a volume-selected rectangular phantom containing a solution of 50 mmol/l KCl and 150 mmol/l glycogen at the same coordinates relative to the coil. The phantom was raised 2.5 cm above the surface of the coil to simulate liver depth. Spectrometer sensitivity was normalized between phantom and in vivo measurements with the signal from the formate sphere as a calibration standard. Resonances from the C-1 glycosyl units in liver glycogen have been shown to be ~100% visible by this method in vivo (9). Reproducibility of the glycogen concentration measurement was assessed in an earlier study with a coefficient of variation between the pairs of measurements of 7%. The standard deviation in the 13C NMR glycogen concentration measurement due to spectral noise was ±5% (40).
2H2O. Body water was assumed to be 50% of body weight in women and 60% in men (46).
Analyses. Plasma glucose concentrations were measured by the glucose oxidase method (Glucose Analyzer II; Beckman Instruments, Palo Alto, CA). Plasma lactate concentrations were measured using the lactate dehydrogenase method (11). Plasma immunoreactive free insulin, glucagon, and cortisol were measured using commercial double-antibody radioimmunoassay kits (insulin: Diagnostic Systems Laboratories, Webster, TX; glucagon: Linco Research, St. Charles, MO; cortisol: Diagnostic Product, Los Angeles, CA). Plasma triglyceride and free fatty acid (FFA) concentrations were determined using a microfluorimetric method (27). Plasma concentrations of total and free insulin-like growth factor (IGF)-I as well as binding proteins 1 and 3 were measured using commercial kits (Nichol's Diagnostic Institute, San Juan Capistrano, CA). Enrichments of the hydrogens at C-2 and C-5 of blood glucose were determined as previously described (21). Protein was precipitated from the blood by the addition of 0.3 N ZnSO4 and 0.3 N Ba(OH)2, and the mixture was centrifuged. The supernatant was deionized by passage through a column of anion and cation exchange resins, and glucose in the effluent was isolated using HPLC. An aliquot of the glucose was converted to xylose, and the xylose was oxidized with periodate to yield C-5 of glucose with its hydrogen in formaldehyde. Hexamethylenetetramine (HMT) was prepared from the formaldehyde and was assayed for mass m + 1 (14, 20, 21). Another aliquot of the glucose was converted to ribulose-5 phosphate (P), which was reduced to a mixture of ribitol-5-P and arabitol-5-P. They were also oxidized with periodate, yielding formaldehyde containing C-2 with its hydrogen. Again, the formaldehyde was condensed to form an HMT, which was assayed for mass (m + 1). In each subject, enrichments of C-2 and C-5 of glucose from blood were determined four times (14.5, 15.5, 17.5, and 18.5 h). The enrichment at C-2 and C-5 at 18.5 h of fasting was used in the calculations. Enrichments in body water was 100 ± 2% in the control and 94 ± 2% in the cirrhotic subjects of the enrichments at C-2 of glucose from blood collected at 18.5 h of fasting. Enrichments of plasma were determined using an isotope ratio mass spectrometer at Metabolic Solutions (Merrimack, NH). Plasma water weight was assumed to be 94% of plasma volume (6). Plasma glucose collected at 10-min intervals beginning 200 min after the start of the [6,6-2H2]glucose infusion was also oxidized with periodate. The formaldehyde formed, which contained C-6 of the glucose with its hydrogens, was converted into HMT, which was assayed for mass m + 2. Masses were five or more times natural abundance. HMTs from [6,6-2H2]glucose of 0.25, 0.50, 0.75, 1.00, 1.50, 2, and 3% enrichments provided a standard curve. When subjects were given [6,6-2H2]glucose, but not 2H2O, no detectable increase above natural abundance was found in m + 1 of HMTs from C-2 and C-5 of blood glucose (2). Calculations. Rates of glucose production (µmol · kg body wt13C NMR spectroscopy. Rates of net hepatic glycogenolysis were calculated by the slope of the decrease in the liver glycogen concentration mmol/l liver from the maximum liver glycogen content ~5-6 h after ingestion of the meal to the concentration measured in the morning after ~14 h of fast. This slope was multiplied by the liver volume (liter) and was divided by body weight (kg). The NMR-determined rate of gluconeogenesis was calculated as the difference between the rates of glucose production and net glycogenolysis.
2H2O method. The fraction of glucose production from gluconeogenesis was set equal to the ratio of the enrichment of the hydrogens bound to C-5 and to C-2 of blood glucose after oral 2H2O (5 ml/kg body water). Percent gluconeogenesis equals 100 times that fraction. The rate of gluconeogenesis was calculated by multiplying that ratio by the rate of glucose production.
Statistics. Data are given as means ± SE. Differences between groups were assessed with the nonparametric Mann-Whitney test. ![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Fasting plasma concentrations of glucose, insulin, glucagon, cortisol,
and FFA are shown in Table 1. Plasma
concentrations of glucose, lactate, and cortisol were similar between
the two groups, whereas plasma FFA (P = 0.01), insulin (P < 0.01), and glucagon (P < 0.01) concentrations
were two- to threefold higher in the cirrhotic subjects. Plasma
concentrations of total and free IGF-I were fourfold lower (25%) in
the cirrhotic subjects compared with the concentrations in the control
subjects (P < 0.01; Table
2). The plasma concentrations of IGF-I
binding protein-3 in the cirrhotic subjects were ~50% lower than in
the control subjects (P < 0.01),
whereas the concentrations of binding protein-1 were twofold increased
in the cirrhotic subjects compared with the control subjects
(P = 0.02; Table 2).
|
|
On a separate occasion, blood was collected before and for 5 h after ingestion of the meal in six of the cirrhotic subjects to test their glucose tolerance to this large liquid meal. Plasma glucose concentrations before and after the liquid meal were 5.4 ± 0.2 mmol/l; 30 min: 8.9 ± 0.4; 1 h: 7.2 ± 0.7; 2 h: 7.7 ± 0.7; 3 h: 7.7 ± 0.8; 4 h: 7.3 ± 0.9; and 5 h: 6.0 ± 0.6 mmol/l (n = 6).
The liver glycogen concentration 5-6 h after the evening meal
(10:00-11:00 PM) was significantly reduced in the cirrhotic subjects (226 ± 16 mmol/l liver compared with the healthy control subjects (343 ± 17 mmol/l liver;
P = 0.007; Fig.
1A).
The mean liver volume as measured by MRI was similar in the two groups of subjects (cirrhotic subjects: 1.62 ± 0.21 liters vs. healthy subjects: 1.62 ± 0.21 liters), although there was a wider range of
liver volumes in the cirrhotic (0.95-2.79 liters) than in the control group (1.23-2.28 liters). Total hepatic glycogen content, calculated as the product of hepatic glycogen concentration and the
MRI-determined liver volume, was significantly higher in the control
group (548 ± 55 mmol) than in the cirrhotic group (364 ± 47 mmol; P = 0.06).
|
During the overnight fast, the rate of net hepatic glycogenolysis,
calculated as the product of the net hepatic glycogen content during
the overnight fast (mmol/l liver) and the MRI-determined liver volume
(liter), was only 0.058 ± 0.020 mmol · l
liver1 · min
1
in the cirrhotic subjects, which was approximately one-third the rate
in the control subjects (0.193 ± 0.027 mmol · l
liver
1 · min
1;
P = 0.01). Hepatic glycogen content
13-14 h after the meal (Fig. 1A) was 246 ± 29 mmol/l in the
control and 198 ± 15 mmol/l in the cirrhotic subjects
(P = 0.17).
Glucose production as determined by
[6,6-2H2]glucose
was similar in the two groups of subjects as recorded in Table
3. The rate of gluconeogenesis for each
group of subjects as determined by the difference between rates of
glucose production and the 13C
NMR-determined rates of net hepatic glycogenolysis expressed per
kilogram body weight are shown in Table 3. The relative contribution of
gluconeogenesis to overall rates of glucose production was significantly increased compared with the healthy control subjects, whereas the absolute rates of gluconeogenesis tended to be higher in
the cirrhotic than in the control subjects.
|
As determined by the
2H2O
method from the 2H enrichment at
C-5 to C-2 (Fig. 1B), the percent
contribution of gluconeogenesis to glucose production was also
significantly higher at 18.5 h of fast (11:30 AM) in the cirrhotic (68 ± 3%) than in the control subjects (54 ± 2%;
P = 0.02). There tended to be a small,
gradual increase in the contribution over the 4 h of blood collection (from 7:30 to 11:30 AM; Fig. 1B).
The absolute rates of gluconeogenesis, calculated by multiplying the
percent gluconeogenesis at 18.5 h by the rate of glucose production,
tended to be higher in the cirrhotic subjects (6.2 ± 0.8 µmol · kg body
wt1 · min
1)
compared with the control subjects (5.3 ± 0.4 µmol · kg body wt
1 · min
1)
but did not reach statistical significance
(P = 0.19). The percent contribution of gluconeogenesis calculated from the ratio of the enrichment at C-5 to that in body water (2, 21) was 72 ± 4% in the
cirrhotic subjects and again 54 ± 2% in the control subjects
(P = 0.008). The absolute rate of
gluconeogenesis was then 6.5 ± 0.7 µmol · kg
1 · min
1
in the cirrhotic subjects and again 5.3 ± 0.3 µmol · kg
1 · min
1
in the control subjects (P = 0.19).
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
There was a marked difference between the hepatic glycogen concentrations in the cirrhotic subjects and the healthy control subjects, despite following a similar dietary regimen for 3 days before the study and an identical evening meal on the day of the study. Hepatic glycogen concentrations in the cirrhotic subjects were 34% lower than in the control subjects at 11:00 PM when glycogen stores typically reach the maximum concentration (12, 31). The low hepatic glycogen content may be due to a net loss of functioning hepatocytes that are replaced by fibrosis and malfunctioning immature hepatocytes, and/or it may be due to portosystemic shunting so that absorbed carbohydrates from the gut are disposed of peripherally. Alternatively, low hepatic glycogen content could also be due to the chronically elevated glucagon levels that were observed in the cirrhotic subjects and that have also been observed previously (44). After the overnight fast, the hepatic glycogen concentrations in the cirrhotic subjects were similar to the fasting glycogen levels in the normal subjects. There are no earlier reports of liver glycogen content in cirrhotic subjects in the fed state. However, hepatic glycogen concentrations were found to be lower in liver biopsies from eight subjects with liver cirrhosis (143 ± 20 mmol/l liver) compared with two overnight-fasted healthy subjects (178 and 267 mmol/l liver; see Ref. 29). Handling of the biopsy tissue requires rapid sampling and freezing to minimize glycogen degradation that occurs during and after removing the liver tissue. Furthermore, sampling error due to the small size of the liver biopsy is likely to be substantial in situations with unequal distribution of glycogen, which is likely in liver cirrhosis. These sources of error may explain why the fasting glycogen content in the healthy and cirrhotic subjects was lower in the previous study than in the present study. After the overnight fast, hepatic glycogen stores changed minimally in the cirrhotic subjects, resulting in rates of net hepatic glycogenolysis that were 66% lower than in the control subjects.
Glucose production measured after 18.5 h of fasting was similar in the control and cirrhotic subjects, which is consistent with most (5, 16, 17, 32-34, 39, 45) but not all previous studies in which glucose production was found to be decreased (13, 26, 29, 36). Cirrhosis is a heterogenous disease with many causes (alcoholic, viral, biliary, etc.), and it is possible that the type and staging of chronic liver failure may contribute to these differences.
We found the relative contribution of gluconeogenesis to glucose production during the overnight fast to be similar by both methods in the control subjects (2H2O method: 54 ± 2%, 13C NMR: 60 ± 10%) and increased in the cirrhotic subjects (2H2O method: 68 ± 3%, 13C NMR: 87 ± 5%). Although the relative contribution of gluconeogenesis to glucose production was higher in the cirrhotic subjects by the 13C NMR method compared with the 2H2O method, these methods measure different processes.
The 13C NMR technique provides a direct measure of hepatic glycogen content and rate of net hepatic glycogenolysis during the fast and demonstrated a markedly lower rate of net hepatic glycogenolysis in the cirrhotic subjects. The rate of glycogenolysis estimated using 13C NMR is the average rate over the 8-h period. The calculated rate of gluconeogenesis is also the average then for that period. However, that calculation depends on the measurement of glucose production hours later. Glucose production may remain the same or decrease during those 4 h (2, 31). Therefore, the contribution of gluconeogenesis would be expected to have been the same or somewhat more, if glucose production had been measured during the 8-h period between the first and the second 13C NMR measurement.
On the other hand, the C-5/C-2 ratio in blood glucose provides a direct
measure of the contribution of gluconeogenesis to glucose production
not only at the time of blood collection but also glucose formed at
earlier times. Percent gluconeogenesis may be underestimated to the
extent that the relative contribution of gluconeogenesis to glucose
production increases during the study. However, because the increase
was only a few percent per hour, at the rate of glucose production,
this underestimate is likely to be small. Gluconeogenesis using the
C-5/C-2 ratio will be overestimated to the extent
glucose-6-P before its conversion to
glucose 1) undergoes triose
phosphate cycling (glycogen glucose-6-P
triose phosphate
glucose-6-P
glucose), 2) is metabolized in the
pentose cycle (23), or 3)
experiences the transaldolase exchange reactions (22).
Triose phosphate cycling results in an overestimation of 2-3% as
evidenced by the 3H bound to C-1
and C-6 of blood glucose produced in normal subjects fasted overnight
and infused with
[1-3H]galactose
(Landau, unpublished observation). A similar percent overestimate may
be due to pentose cycle activity (23, 25). The contribution of the
transaldolase reaction is also likely to be small but is yet to be
quantitated. Evidence that the sum of these contributions is small is
the similar estimates by the two methods of the contributions to
glucose production of gluconeogenesis in the normal subjects. Triose
phosphate cycling, pentose cycle, and transaldolase reactions do not
affect estimates by the NMR method.
With the use of the C-5/C-2 ratio, equilibration between glucose-6-P and fructose-6-P is assumed to be so rapid that the hydrogen bound to C-2 of glucose released into the blood has the enrichment of body water (24). Similar enrichments at C-2 and in body water at 18.5 h of fasting supports that assumption. Enrichment at C-2 has also been found to be 90% or more of that in body water in other studies in humans (4, 13, 24). In accord with that 1) when hepatocytes from fasted rats were incubated with lactate, pyruvate, and 3H2O, label of the hydrogen C-2 of the glucose formed was ~100% of that in the water (38) and 2) when hepatocytes were incubated with glucose in the presence of 2H2O or 3H2O and when rats were given 3H2O and glucose, the hydrogen at C-2 of glucose from the glycogen that formed was ~90% labeled (19, 35, 49). In normal subjects fasted overnight, only 80% of 3H of [2-3H]galactose was removed in its conversion to glucose (48). However, there is an isotope effect in the detritiation of [2-3H]glucose-6-P (15, 49).
The reason for the apparently greater contribution of gluconeogenesis to glucose production, estimated by the 13C NMR rather than the 2H2O method, most clearly evident in the cirrhotic subjects, is uncertain. To the extent glycogen cycling occurs (10, 24, 37), the 2H2O method gives an underestimate of the contribution. That is because [2-2H]glucose would be released from glycogen while [2,5-2H]glycogen would be formed. However, estimates were made only beginning 6 h after the end of the 2H2O ingestion. With time after ingestion, the effect of glycogen cycling diminishes, because glucose released from the glycogen then becomes increasingly 2,5-2H2 labeled. Glycogen cycling has no effect on the 13C NMR measurements, which measure net changes in hepatic glycogen content.
Hepatic glycogen cycling can be extensive under certain hyperinsulinemic (24, 30) and hyperglucagonemic conditions (37). Although cycling is undetectable in healthy humans after an overnight fast (30), the hyperglucagonemic conditions in the cirrhotic subjects possibly promoted cycling. This could explain the better agreement in the estimates of the contribution of gluconeogenesis between the two methods in the control than in the cirrhotic subjects. Glucose production by both liver and kidney is measured using [6,6-2H2]glucose, and the total glycogen content of the kidney is minimal compared with the liver. Therefore, differences in estimates by the two methods are unlikely to be due to renal metabolism.
The contribution of gluconeogenesis as determined by 13C NMR spectroscopy assumes that the carbohydrate of the meal was absorbed into the blood between the ingestion of the meal and the first 13C NMR measurement of hepatic glycogen content; therefore, a liquid meal was given to favor rapid absorption (31). Also, there was no significant difference between plasma glucose concentration in the cirrhotic subjects at the time of meal intake and the time the measurement of hepatic glycogen content was initiated, i.e., 5 h. Still, if only 1.3 g glucose from the meal were absorbed per hour during the 8-h period, the estimate of gluconeogenesis in the cirrhotic subjects would decrease from a mean of ~87 to 71%. That rate of absorption would not be expected to be increasing the plasma glucose concentration above the fasting level. A plasma concentration 1 mmol/l higher at 5 h than before the meal, assuming a distribution of glucose in body water of 20 liters, would mean the "storing" of 3.6 g of glucose from the meal in that space. Return to the premeal glucose concentration during the 8-h period would reduce the estimate of the contribution of gluconeogenesis by ~5%.
Chronically elevated plasma concentrations of both glucagon and FFA might contribute to the relative increase in gluconeogenesis that was observed in the cirrhotic subjects. Consistent with this possibility are the data obtained by Keller et al. (17), who demonstrated a greater reduction in net splanchnic glucose production in cirrhotic subjects than in control subjects when somatostatin was used to suppress plasma glucagon concentrations. Similarly increased concentrations of FFA have been reported to increase hepatic gluconeogenesis in human subjects (3, 47), possibly by increasing intracellular acetyl-CoA concentrations and thereby activating pyruvate carboxylase (1).
Another factor that might contribute to the higher relative gluconeogenesis in the cirrhotic subjects is the lower plasma concentration of IGF-I (total and free IGF-I) in subjects with liver cirrhosis. The lower concentration of IGF-I can be attributed to a diminished hepatic synthesis, consistent with earlier observations (28, 42, 43). Although the implications of IGF-I deficiency are not fully understood, possibly lower levels of free IGF-I could contribute to the catabolic state in cirrhotic subjects by promoting muscle proteolysis, which in turn might provide more amino acids to the liver for gluconeogenesis (7, 8, 41).
In summary, we examined hepatic glycogenolysis and gluconeogenesis using two independent methods and found that cirrhotic subjects have increased contributions of gluconeogenesis and decreased contributions of net hepatic glycogenolysis to glucose production compared with control subjects. These alterations are likely important contributing factors to their altered carbohydrate metabolism and may at least in part be attributed to chronically increased plasma glucagon and FFA concentrations and/or decreased plasma IGF-I levels.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Veronika Walton, Laura Burden, Danica Barron, and Kathy Camputaro for expert technical assistance and the staff of the Yale-New Haven Hospital General Clinical Research Center.
![]() |
FOOTNOTES |
---|
This work was supported in part by National Institutes of Health (NIH) Grants RO1 DK-49230, RO1 DK-45735, RO1 DK-14507, and MO1 RR-00125. K. F. Petersen was the recipient of an NIH Clinical Associate Physician Award. G. I. Shulman is an investigator of the Howard Hughes Medical Institute.
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for correspondence and reprint requests: K. Falk Petersen, Yale Univ. School of Medicine, Dept. of Internal Medicine, PO Box 208020, New Haven, CT 06520-8020 (E-mail: Kitt.Petersen{at}Yale.edu).
Received 20 April 1998; accepted in final form 4 November 1998.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Bahl, J. J.,
M. Matsuda,
R. A. DeFronzo,
and
R. Bressler.
In vitro and in vivo suppression of gluconeogenesis by inhibition of pyruvate carboxylase.
Biochem. Pharmacol.
53:
67-74,
1997[Medline].
2.
Chandramouli, V.,
K. Ekberg,
W. C. Schumann,
S. C. Kalhan,
J. Wahren,
and
B. R. Landau.
Quantifying gluconeogenesis during fasting.
Am. J. Physiol.
273 (Endocrinol. Metab. 36):
E1209-E1215,
1997[Medline].
3.
Clore, J. N.,
P. S. Glickman,
J. E. Nestler,
and
W. G. Blackard.
In vivo evidence for hepatic autoregulation during FFA-stimulated gluconeogenesis in normal humans.
Am. J. Physiol.
261 (Endocrinol. Metab. 24):
E425-E429,
1991
4.
Dekker, E.,
J. A. Romijn,
K. Ekberg,
J. Wahren,
H. Van Thien,
M. T. Ackermans,
L. T. Thuy,
V. Chandramouli,
P. A. Kager,
B. R. Landau,
and
H. P. Sauerwein.
Glucose production and gluconeogenesis in adults with uncomplicated falciparum malaria.
Am. J. Physiol.
272 (Endocrinol. Metab. 35):
E1059-E1064,
1997
5.
DeLissio, M.,
L. J. Goodyear,
S. Fuller,
E. L. Krawitt,
and
J. T. Devlin.
Effects of treadmill exercise on fuel metabolism in hepatic cirrhosis.
J. Appl. Physiol.
70:
210-215,
1991
6.
Dittmer, D.
Blood and other bodily fluids.
In: Biological Handbooks. Washington, DC: Fed. Am. Soc. Exp. Biol., 1961, p. 186.
7.
Fryburg, D. A.,
L. A. Jahn,
S. A. Hill,
D. M. Oliveras,
and
E. J. Barrett.
Insulin and insulin-like growth factor-I enhance human skeletal muscle protein anabolism during hyperaminoacidemia by different mechanisms.
J. Clin. Invest.
96:
1722-1729,
1995[Medline].
8.
Grøfte, T.,
T. Wolthers,
S. A. Jensen,
N. Møller,
J. O. Jørgensen,
N. Tygstrup,
H. Ørskov,
and
H. Vilstrup.
Effects of growth hormone and insulin-like growth factor-I singly and in combination on in vivo capacity of urea synthesis, gene expression of urea cycle enzymes, and organ nitrogen contents in rats.
Hepatology
25:
964-969,
1997[Medline].
9.
Gruetter, R.,
I. Magnusson,
D. L. Rothman,
M. J. Avison,
R. G. Shulman,
and
G. I. Shulman.
Validation of 13C NMR measurements of liver glycogen in vivo.
Magn. Reson. Med.
31:
583-588,
1994[Medline].
10.
Hellerstein, M. K.,
R. A. Neese,
A. Letscher,
P. Linfoot,
and
S. Turner.
Hepatic glucose-6-phosphatase flux and glucose phosphorylation, cycling, irreversible disposal, and net balance in vivo in rats. Measurement using the secreted glucuronate technique.
Metabolism
46:
1390-1398,
1997[Medline].
11.
Hohorst, H. J.
L-(+)-Lactate determination with lactic dehydrogenase.
In: Methods of Enzymatic Analysis, edited by H. U. Bergmeyer. Basel: Verlag Chemie, 1965, p. 266-70.
12.
Hwang, J. H.,
G. Perseghin,
D. L. Rothman,
G. W. Cline,
I. Magnusson,
K. F. Petersen,
and
G. I. Shulman.
Impaired net hepatic glycogen synthesis in insulin-dependent diabetic subjects during mixed meal ingestion. A 13C nuclear magnetic resonance spectroscopy study.
J. Clin. Invest.
95:
783-787,
1995[Medline].
13.
Johansson, U.,
J. Wahren,
and
L. S. Eriksson.
Splanchnic and peripheral glucose metabolism in cirrhosis.
J. Hepatol.
20:
760-767,
1994[Medline].
14.
Kalhan, S. C.,
R. Trivedi,
S. Singh,
V. Chandramouli,
W. C. Schumann,
and
B. R. Landau.
A micromethod for measurement of deuterium bound to carbon 6 of glucose to quantify gluconeogenesis in vivo.
J. Mass Spectrom.
30:
1588-1592,
1995.
15.
Katz, J.,
P. A. Wals,
and
R. Rognstad.
Glucose phosphorylation, glucose-6-phosphatase, and recycling in rat hepatocytes.
J. Biol. Chem.
253:
4530-4536,
1978[Medline].
16.
Kaye, G. L.,
Y. T. Kruszynska,
D. S. Harry,
K. Heslop,
D. G. Johnston,
and
N. McIntyre.
Lipid metabolism and insulin resistance in cirrhosis.
J. Hepatol.
20:
782-791,
1994[Medline].
17.
Keller, U.,
G. E. Sonnenberg,
D. Burckhardt,
and
A. Perruchoud.
Evidence for an augmented glucagon dependence of hepatic glucose production in cirrhosis of the liver.
J. Clin. Endocrinol. Metab.
54:
961-968,
1982[Abstract].
18.
Kruszynska, Y. T.,
and
N. McIntyre.
Gluconeogenesis from glycerol is not increased in overnight fasted cirrhotic patients (Abstract).
Hepatology
19:
A197,
1994.
19.
Kuwajima, M.,
S. Golden,
J. Katz,
R. H. Unger,
D. W. Foster,
and
J. D. McGarry.
Active hepatic glycogen synthesis from gluconeogenic precursors despite high tissue levels of fructose 2,6-bisphosphate.
J. Biol. Chem.
261:
2632-2637,
1986
20.
Landau, B. R.,
J. Wahren,
V. Chandramouli,
W. C. Schumann,
K. Ekberg,
and
S. C. Kalhan.
Use of 2H2O for estimating rates of gluconeogenesis. Application to the fasted state.
J. Clin. Invest.
95:
172-178,
1995[Medline].
21.
Landau, B. R.,
J. Wahren,
V. Chandramouli,
W. C. Schumann,
K. Ekberg,
and
S. C. Kalhan.
Contributions of gluconeogenesis to glucose production in the fasted state.
J. Clin. Invest.
98:
378-385,
1996
22.
Ljungdahl, L.,
H. G. Wood,
E. Racker,
and
D. Couri.
Formation of unequally labeled fructose-6-phosphate by an exchange reaction catalyzed by transaldolase.
J. Biol. Chem.
236:
1622-1625,
1961[Medline].
23.
Magnusson, I.,
V. Chandramouli,
W. C. Schumann,
K. Kumaran,
J. Wahren,
and
B. R. Landau.
Pentose pathway in human liver.
Proc. Natl. Acad. Sci. USA
85:
4682-4685,
1988[Abstract].
24.
Magnusson, I.,
D. L. Rothman,
B. Jucker,
G. W. Cline,
R. G. Shulman,
and
G. I. Shulman.
Liver glycogen turnover in fed and fasted humans.
Am. J. Physiol.
266 (Endocrinol. Metab. 29):
E796-E803,
1994
25.
Magnusson, I.,
A. Wennlund,
V. Chandramouli,
W. C. Schumann,
K. Kumaran,
J. Wahren,
and
B. R. Landau.
Fructose-6-phosphate cycling and the pentose cycle in hyperthyroidism.
J. Clin. Endocrinol. Metab.
70:
461-466,
1990[Abstract].
26.
Merli, M.,
L. S. Eriksson,
L. Hagenfeldt,
and
J. Wahren.
Splanchnic and leg exchange of free fatty acids in patients with liver cirrhosis.
J. Hepatol.
3:
348-355,
1986[Medline].
27.
Miles, J.,
R. Glasscock,
J. Aikens,
J. Gerich,
and
M. Haymond.
A microfluorometric method for the determination of free fatty acids in plasma.
J. Lipid Res.
24:
96-99,
1983[Abstract].
28.
Moller, S.,
and
U. Becker.
Insulin-like growth factor I and growth hormone in chronic liver disease.
Dig. Dis.
10:
239-248,
1992[Medline].
29.
Owen, O. E.,
F. A. Reichle,
M. A. Mozzoli,
T. Kreulen,
M. S. Patel,
I. B. Elfenbein,
M. Golsorkhi,
K. H. Chang,
N. S. Rao,
H. S. Sue,
and
G. Boden.
Hepatic, gut, and renal substrate flux rates in patients with hepatic cirrhosis.
J. Clin. Invest.
68:
240-252,
1981[Medline].
30.
Petersen, K. F.,
D. Laurent,
D. L. Rothman,
G. W. Cline,
and
G. I. Shulman.
Mechanism by which glucose and insulin inhibit net hepatic glycogenolysis in humans.
J. Clin. Invest.
101:
1203-1209,
1998
31.
Petersen, K. F.,
T. Price,
G. W. Cline,
D. L. Rothman,
and
G. I. Shulman.
Contribution of net hepatic glycogenolysis to glucose production during the early postprandial period.
Am. J. Physiol.
270 (Endocrinol. Metab. 33):
E186-E191,
1996
32.
Petrides, A. S.,
and
R. A. De Fronzo.
Failure of glucagon to stimulate hepatic glycogenolysis in well-nourished patients with mild cirrhosis.
Metabolism
43:
85-89,
1994[Medline].
33.
Petrides, A. S.,
L. C. Groop,
C. A. Riely,
and
R. A. DeFronzo.
Effect of physiologic hyperinsulinemia on glucose and lipid metabolism in cirrhosis.
J. Clin. Invest.
88:
561-570,
1991[Medline].
34.
Petrides, A. S.,
C. Vogt,
D. Schulze-Berge,
D. Matthews,
and
G. Strohmeyer.
Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis.
Hepatology
19:
616-627,
1994[Medline].
35.
Postle, A. D.,
and
D. P. Bloxham.
The use of tritiated water to measure absolute rates of hepatic glycogen synthesis.
Biochem. J.
192:
65-73,
1980[Medline].
36.
Reichle, F. A.,
O. E. Owen,
M. Golsorkhi,
and
T. Kreulen.
Hepatic metabolism in patients with alcoholic cirrhosis.
Surgery
84:
33-36,
1978[Medline].
37.
Roden, M.,
G. Perseghin,
K. F. Petersen,
J. H. Hwang,
G. W. Cline,
K. Gerow,
D. L. Rothman,
and
G. I. Shulman.
The roles of insulin and glucagon in the regulation of hepatic glycogen synthesis and turnover in humans.
J. Clin. Invest.
97:
642-648,
1996
38.
Rognstad, R.,
G. Clark,
and
J. Katz.
Glucose synthesis in tritiated water.
Eur. J. Biochem.
47:
383-388,
1974[Medline].
39.
Romijin, J. A.,
E. Endert,
and
H. P. Sauerwein.
Glucose and fat metabolism during short-term starvation in cirrhosis.
Gastroenterology
100:
731-737,
1991[Medline].
40.
Rothman, D. L.,
I. Magnusson,
L. D. Katz,
R. G. Shulman,
and
G. I. Shulman.
Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR.
Science
254:
573-576,
1991[Medline].
41.
Sandström, R.,
E. Svanberg,
A. Hyltander,
E. Haglind,
C. Ohlsson,
H. Zachrisson,
B. Berglund,
E. Lindholm,
H. Brevinge,
and
K. Lundholm.
The effect of recombinant human IGF-I on protein metabolism in post-operative patients without nutrition compared to effects in experimental animals.
Eur. J. Clin. Invest.
25:
784-792,
1995[Medline].
42.
Santolaria, F.,
G. Gonzalez-Gonzalez,
E. Gonzalez-Reimers,
A. Martinez-Riera,
A. Milena,
F. Rodriguez-Moreno,
and
C. Gonzalez-Garcia.
Effects of alcohol and liver cirrhosis on the GH-IGF-I axis.
Alcohol
30:
703-708,
1995.
43.
Sheppard, M. S.,
G. Y. Minuk,
B. Bhaumick,
and
R. M. Bala.
Insulin-like growth factors (IGF) in liver disease: differential changes of IGF-I and IGF-II.
Clin. Invest. Med.
10:
49-53,
1987[Medline].
44.
Sherwin, R. S.,
M. Fisher,
J. Bessoff,
N. Snyder,
R. Hendler,
H. O. Conn,
and
P. Felig.
Hyperglucagonemia in cirrhosis: altered secretion and sensitivity to glucagon.
Gastroenterology
74:
1224-1228,
1978[Medline].
45.
Shmueli, E.,
M. Walker,
G. Alberti,
and
C. O. Record.
Normal splanchnic but impaired peripheral insulin-stimulated glucose uptake in cirrhosis.
Hepatology
18:
86-95,
1993[Medline].
46.
Taylor, C. B.,
B. Mikkelson,
J. A. Anderson,
and
D. T. Forman.
Human serum cholesterol synthesis measured with the deuterium label.
Arch. Pathol.
8:
213-232,
1966.
47.
Wahren, J.,
L. Hagenfeldt,
and
P. Felig.
Splanchnic and leg exchange of glucose, amino acids, and free fatty acids during exercise in diabetes mellitus.
J. Clin. Invest.
55:
1303-1314,
1975[Medline].
48.
Wajngot, A.,
V. Chandramouli,
W. C. Schumann,
K. Kumaran,
S. Efendic,
and
B. R. Landau.
Testing of the assumptions made in estimating the extent of futile cycling.
Am. J. Physiol.
256 (Endocrinol. Metab. 19):
E668-E675,
1989
49.
Wals, P. A.,
and
J. Katz.
Glucose-glucose 6-phosphate cycling in hepatocytes determined by incorporation of 3HOH and D2O. Effect of glycosyns and fructose.
J. Biol. Chem.
269:
18343-18352,
1994